Heparin-induced thrombocytopenia

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 7, 2003, Pages 1471-1478

  Chong, B H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antibody; Heparin; Platelets; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; EPITOPE; HEPARIN;

ANIMAL; BIOLOGICAL MODEL; HUMAN; IMMUNOASSAY; METABOLISM; MOUSE; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTICOAGULANTS; ENDOTHELIUM, VASCULAR; EPITOPES; HEPARIN; HUMANS; IMMUNOASSAY; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0141609865     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00270.x     Document Type: Review

References (94)

1. Chong BH. Heparin induced thrombocytopenia. Br J Haematol 1995; 89: 431-9.
2. Chong BH. Heparin induced thrombocytopenia. Blood Rev 1988; 2: 108-14.
3. Warketin TE, Chong BH, Greinacher A. Heparin induced thrombocytopenia: towards consensus. Thromb Haemostas 1998; 79: 1-7.
4. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complication with a heparin-dependent igg antibody which induced platelet aggregation, release and thromboxane synthesis. Lancet 1982; ii: 1246-8.
5. Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 1989; 58: 53-7.
6. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
7. Chong BH, Ismail F. The mechanism of heparin-induced platelet aggregation. Eur J Haematol 1989; 43: 245-51.
8. Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 1997; 58: 270-85.
9. Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
10. Horne MK III, Hutchinson KJ. Simultaneous binding of heparin and platelet Factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998; 58: 24-30.
11. Visentin GP, Moghaddam M, Collins JL, McFarland JG, Aster RH. Antibodies associated with heparin-induced thrombocytopenia (HIT) report conformational changes in platelet factor 4 (PF4) induced by linear polyanionic compounds. Blood 1997; 90 (Suppl. 1): 460a [Abstract].
12. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 886-92.
13. Horne MK III. Nonimmune heparin-platelet interactions. Implications for the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin, T E, Greinacher, A, eds. Heparin-Induced Thrombocytopenia 1st edn. New York, Basel: Marcel Dekker. 2000:113-26.
14. Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 65-76.
15. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med 1996; 128: 376-83.
16. Newman P, Chong BH. Heparin-induced thrombocytopenia. The major antigenic epitope is on the modified platelet factor 4 and not on heparin. Br J Haematol 1999; 107: 303-9.
17. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood 1998; 72: 925-30.
18. Chong BH, Ismail F, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73: 235-40.
19. Chong BH, Grace CS, Rosenberg MC. Heparin-induced thrombocytopenia: effects of heparin platelet antibody on platelets. Br J Haem 1981; 49: 531-40.
20. Newman P, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resulting activation. Blood 2000; 96: 182-7.
21. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generated platelet-derived microparticles with procoagulant activity. an explanation for the thrombotic complications of heparin-induced thrombocytopenia.. Blood 1994; 84: 3691-9.
22. Reilly MP, Taylor SM, Hartman NK, Arepally GM, Cines DB, Poncz M, McKenzie SE. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model demonstrates the requirement for human platelet factor 4 and platelet activation through FcγRIIA. Blood 2000; 96: 221a [Abstract].
23. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 581-9.
24. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8.
25. Amiral J, Wolf M, Fischer AM, Boyer-Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 945-9.
26. Amiral J, Peynaud-Debayle E, Wolf M, Brideym F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low molecular weight heparin. Am J Hematol 1996; 52: 90-5.
27. Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, Vissac AM, Fressinaud E, Poncz M, Meyer DA. Presence of auto-antibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated-thrombocytopenia. Blood 1996; 88: 410-6.
28. Bell WR, Tomasulo PA, Alving BM, Duffy TP. Thrombocytopenia occurring during the administration of heparin. a prospective study in 52 patients. Ann Intern Med 1976; 85: 155-60.
29. Gallus AS, Goodall KT, Beswick W, Chesterman CN. Heparin-associated thrombocytopenia: a case report and prospective study. Aust NZ J Med 1980; 10: 25-31.
30. Powers PJ, Kelton JG, Carter CJ. Studies of the frequency of heparinassociated thrombocytopenia. Thromb Res 1984; 33: 439-43.
31. Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Ramirez-Lassepas M. Heparin-associated thrombocytopenia. A prospective evaluation of 211 patients. Ther Drug Monit 1983; 5: 205-11.
32. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 1st edn. New York: Marcel Dekker, Inc. 2000: 81-112.
33. Chong BH. Heparin-induced thrombocytopenia. In: Michelson AD, ed. Platelets, 1st edn. London: Academic Press. 2002: 571-91.
34. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and a pooled analysis. Am J Med Sci 1993; 305: 208-15.
35. Malcolm ID,Wigmore TA, Steinbrecher UP. Heparin-associated thrombocytopenia: low frequency in 104 patients treated with heparin of intestinal mucosal origin. Can Med Assoc J 1979; 120: 1086-8.
36. Green D, Martin GJ, Shoichet SH, DeBacker N, Bomalaski MS, Lind RN. Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin. Am J Med Sci 1984; 288: 60-4.
37. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
38. Leyvraz PF, Bachmann F, Hoek J, Büller HR, Postel M, Samama M, Vandenbroek MD. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin and low molecular weight heparin. BMJ 1991; 303: 543-8.
39. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass. Br J Haematol 1998; 101: 653-5.
40. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a lowmolecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-3536.
41. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparininduced thrombocytopenia. Blood 2000; 96: 1703-8.
42. Visentin GP, Mali M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin platelet factor 4 complexes. J Lab Clin Med 1996; 128: 376-83.
43. Bauer TL, Arepally G, Konkle BA, Mestichelli BMT, Shapiro SS, Cines DB, Poncz M, McNulty SDO, Amiral J, HauckWW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242-6.
44. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 1st edn. New York: Marcel Dekker. 2000:43-80.
45. Boshkov LK, Warkentin TE, Hayward CPM, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-8.
46. Warkentin TE, Hong AP. Frequency of upper limb deep venous thrombosis (UL-DVT) in relation to central venous catheter (CVC) use in patients with heparin-induced thrombocytopenia (HIT): evidence for interaction of systemic (HIT) and local (CVC) prothrombotic risk factors. Blood 1998; 92 (Suppl. 1): 500a-501a [Abstract].
47. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12.
48. Klein HG, Bell WR. Disseminated intravascular coagulation during heparin therapy. Intern Med 1974; 80: 477-48.
49. Rhodes GR, Dixon RH, Silver D. Heparin-induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973; 136: 409-16.
50. Popov D, Zarrabi MH, Foda H, Graber M. Pseudopulmonary embolism. Acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis 1997; 29: 449-52.
51. Warkentin TE, Soutar RL, Panju A, Ginsberg JS. Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin-induced thrombocytopenia. Blood 1992; 80 (Suppl. 1): 160a[Abstract].
52. Warkentin TE, Hirte HW, Anderson DR, Wilson WEC, O'Connell GJ, Lo RC. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994; 97: 489-91.
53. Chong BH. Diagnosis, treatment and pathophysiology of immunemediated thrombocytopenia. Crit Rev Oncol Hematol 1995; 20: 271-96.
54. Chong BH, Eisbacher M. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Sem In Haematol 1998; 35: 53-8.
55. Sheridan D, Carter C, Kelton JG. A Diagnostic test for heparin-induced trombocytopenia. Blood 1986; 67: 27-30.
56. Greinacher A, Michels. J, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-6.
57. Stewart MW, Etches WS, Boshkov LK, Gordon PA. Heparin-induced thrombocytopenia: an improved method of detection based on lumiaggregometry. Br J Haematol 1995; 91: 173-7.
58. Lee DP, Warkentin TE, Denomme GA, Hayward GPM, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996; 95: 724-31.
59. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997; 98: 648-56.
60. Jy W, Mao WW, Horstman LL, Valant PA, Ahn YS. A flow cytometic assay of platelet activation markers P-selectin (CW 62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 1999; 82: 1255-9.
61. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344-50.
62. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 371-9.
63. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998; 80: 292-7.
64. Meyer O SalamaA, Pitter N, Schwind P. Rapid detection of heparininduced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 1999; 3534: 1525-6.
65. Chong BH. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 1st edn. New York: Marcel Dekker. 2000: 291-311.
66. Chong BH, Magnani HN. Orgaran in Heparin-induced Thrombocytopenia. Haemostasis 1992; 22: 85-91.
67. Magnani HN. Heparin-induced thrombocytopenia. (HIT): an overview of 230 patients treated with orgaran (Org. 10172). Thromb Haemost 1993; 70: 554-61.
68. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velton HG, Pötsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80.
69. Greinacher A, Janssens U, Berg G, Böck M, Kwasny H, Kemkes-Matthes B, Eichler P, Völpel H, Pötzsch B, Luz M. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparininduced thrombocytopenia. Circulation 1999; 100: 587-93.
70. Lubenow N, Greinacher A. Heparin-induced thrombocytopenia. Recommendations for optimal use of recombinant hirudin. Biodrugs 2000; 14: 109-25.
71. Lewis BE, Wallis DE, Berakowitz SD, Matthai WH, for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1038-43.
72. Cohen JI, Cooper MR, Greenberg GS. Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med 1985; 145: 1725-6.
73. Fiessinger JN, Aiach M, Rocanto M, Debure C, Gauz JC. Critical ischemia during heparin-induced thrombocytopenia. Treatment by intra-arterial streptokinase. Thromb Res 1984; 33: 235-8.
74. Sobel M, Adelmann B, Szentpeterey S, Hofmann M, Posner MP, Jenvey W. Surgical management of heparin-associated thrombocytopenia. strategies in the treatment of venous and arterial thromboembolism. J Vasc Surg 1988; 8: 395-401.
75. Meuleman DG. Orgaran (Org. 10172): its pharmacological profile in experimental models. Haemostasis 1992; 22: 58-65.
76. Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on orgaran (Org. 10172). Hemostasis 1992; 22: 73-84.
77. Chong BH, Gallus AS, Cade J, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN; Australian HIT Study Group. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparininduced thrombocytopenia with thrombosis. Thromb Haemost 2001; 86: 1170-5.
78. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Sem In Hematol 1998; 35: 5:3-8.
79. Warkentin TE. Danaparoid (Orgaran) for the treatment of heparininduced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation and evaluation of the clinical significance of in vitro cross-reactivity of danaparoid for HIT-IgG. Blood 1996; 88: 626a [Abstract].
80. Tardy/Poncet B, Mahul P, Beraud AM, Favre JP, Tardy B, Guyotat D. Failure of orgaran therapy in a patient with a previous heparin-induced thrombocytopenia. Br J Haematol 1995; 90: 69-70.
81. Weitz JI, Hudoba M, Massel D, Marganore J, Hirsh J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
82. Greinacher A, Eichler P, Lubenow N. Drug-induced and drug-dependent immune thrombocytopenias. In: Gresele P, Page C, Fuster V, Vermylen J, eds. Platelets in Thrombotic and Nonthrombotic Disorder, 1st edn. Cambridge: Cambridge University Press 2002: 584-609.
83. Glusa E. Pharmacology and therapeutic applications of hirudin, a new anticoagulant. Kidney Int 1998; 53: 54-6.
84. Eichler P, Friesen HJ, Lubenow N, Jaegar B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects of aPTT, and clinical relevance. Blood 2000; 96: 2372-8.
85. Okamoto S, Okunomiya-Hijikata A. Synthetic selective inhibitors of thrombin. Methods 1993; 222: 328-40.
86. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinan hirudin. Thromb Haemost 1994; 72: 381-6.
87. Izawa O, Katsuki M, Komatsu T, Iida S. Pharmacokinetic studies of argatroban (MD-805) in human: concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jap Pharmacol Ther 1986; 14: 251-63.
88. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994; 83: 1535-41.
89. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
90. Reiss FC, Pötzsch B, Bader K, Bleese N, Greinacher A, Löwer C, Madlener K, Müller-Berghaus G. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg 1996; 10: 386-8.
91. Makhoul RG, McCann RL, Austin EH, Greenberg CS, Lowe JE. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann Thorac Surg 1987; 43: 617-21.
92. Van Wyk V, Badenhorst PN, Luus HG, Kotzé HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kid Int 1995; 48: 1338-43.
93. Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997; 109: 354-8.
94. Matsuo T, Kario K, Kodama K, Okamoto S. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Semin Thromb Hemost 1992; 18: 155-60.